Sun Pharma Advanced Research Co (NSE:SPARC) Cyclically Adjusted Revenue per Share: ₹12.10 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
62 GF Score
Price ₹251.04
GF Value ₹4,533.03
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Cyclically Adjusted Revenue per Share?

Sun Pharma Advanced Research Co NSE:SPARC +1.30% 62 Cyclically Adjusted Revenue per Share is ₹12.10 as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 62/100 and a GF Value™ of ₹4,533.03 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sun Pharma Advanced Research Co's adjusted revenue per share for the three months ended in Mar. 2026 was ₹57.101. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹12.10 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Sun Pharma Advanced Research Co's average Cyclically Adjusted Revenue Growth Rate was 70.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sun Pharma Advanced Research Co was 13.30% per year. The lowest was -2.60% per year. And the median was 2.20% per year.

As of today (2026-07-16), Sun Pharma Advanced Research Co's current stock price is ₹251.04. Sun Pharma Advanced Research Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹12.10. Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio of today is 20.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sun Pharma Advanced Research Co was 56.29. The lowest was 10.31. And the median was 26.74.


Sun Pharma Advanced Research Co  (NSE:SPARC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=251.04/12.10
=20.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sun Pharma Advanced Research Co was 56.29. The lowest was 10.31. And the median was 26.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sun Pharma Advanced Research Co Cyclically Adjusted Revenue per Share Related Terms


Sun Pharma Advanced Research Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Cyclically Adjusted Revenue per Share Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.67 8.30 7.67 7.08 12.10

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.08 6.92 6.77 6.60 12.10

NSE:SPARC vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's Cyclically Adjusted PS Ratio falls into.


NSE:SPARC
62GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sun Pharma Advanced Research Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=57.101/164.2724*164.2724
=57.101

Current CPI (Mar. 2026) = 164.2724.

Sun Pharma Advanced Research Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.868 105.961 1.346
201609 3.856 105.961 5.978
201612 0.934 105.196 1.459
201703 1.696 105.196 2.648
201706 0.946 107.109 1.451
201709 0.621 109.021 0.936
201712 0.783 109.404 1.176
201803 0.810 109.786 1.212
201806 0.670 111.317 0.989
201809 2.378 115.142 3.393
201812 0.783 115.142 1.117
201903 3.253 118.202 4.521
201906 0.660 120.880 0.897
201909 0.656 123.175 0.875
201912 0.749 126.235 0.975
202003 0.867 124.705 1.142
202006 7.066 127.000 9.140
202009 0.674 130.118 0.851
202012 0.832 130.889 1.044
202103 1.074 131.771 1.339
202106 0.838 134.084 1.027
202109 1.056 135.847 1.277
202112 2.354 138.161 2.799
202203 0.948 138.822 1.122
202206 1.047 142.347 1.208
202209 1.162 144.661 1.320
202212 4.520 145.763 5.094
202303 1.484 146.865 1.660
202306 0.738 150.280 0.807
202309 0.652 151.492 0.707
202312 0.427 152.924 0.459
202403 0.510 153.035 0.547
202406 0.519 155.789 0.547
202409 0.397 157.882 0.413
202412 0.459 158.323 0.476
202503 0.837 157.552 0.873
202506 0.297 159.755 0.305
202509 0.242 162.289 0.245
202512 0.261 163.281 0.263
202603 57.101 164.272 57.101

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹12.10 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Cyclically Adjusted Revenue per Share of ₹12.10 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's Cyclically Adjusted Revenue per Share too high?
Sun Pharma Advanced Research Co's current Cyclically Adjusted Revenue per Share is ₹12.10. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's Cyclically Adjusted Revenue per Share of ₹12.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Cyclically Adjusted Revenue per Share is ₹12.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,533.03, compared to a current price of ₹251.04 — trading 94.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹12.10. Sun Pharma Advanced Research Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Cyclically Adjusted Revenue per Share is ₹12.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹251.04 is trading 94.5% below its estimated GF Value™ of ₹4,533.03. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Cyclically Adjusted Revenue per Share: ₹12.10
  • GF Value™: ₹4,533.03 vs. price of ₹251.04 (94.5% below fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
62GF Score

Get the complete analysis for NSE:SPARC

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹251.04
Price
₹4,533.03
GF Value